We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Accuri and eBIOSCIENCE Partner to Offer Complete Flow Cytometry Solutions

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Accuri and eBIOSCIENCE Partner to Offer Complete Flow Cytometry Solutions"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Accuri Cytometers, Inc. and eBioscience announced that they have entered into a worldwide co-marketing agreement.

The collaboration is designed to offer scientists a better and more comprehensive solution for their flow cytometry research needs, harnessing ease-of-use, performance capabilities and accessibility of the Accuri C6 Flow Cytometer® System with extensive line of high quality cytometer research reagents offered by eBioscience.

Explicitly designed for routine use by biomedical researchers in their own labs, Accuri’s full-featured bench-top cell analysis system provides capabilities similar to flow cytometers in a user-friendly format and at a fraction of the cost. eBioscience, which is among the largest suppliers of flow cytometry research reagents worldwide, offers a wide range of high quality flow cytometry research reagents optimized for a variety of applications.

Accuri designed the C6 system from the ground up with input from hundreds of researchers. Accuri's innovations, coupled with its components, resulted in a cytometer that is robust, compact, easy-to-use and affordable, at less than one-third the price of current flow cytometers and one-tenth the operating costs of the market leaders over five years of ownership, the companies say.

Further terms of the agreement were not disclosed.